新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn...新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn与IgG的结合,可显著降低致病性IgG水平,从而有效地缓解相关疾病的临床症状。FcRn拮抗剂作为一种新兴的靶向治疗药物,展示了其治疗IgG介导的神经免疫性疾病的潜力。本文对FcRn拮抗剂的作用机制、种类和临床研究进展进行总结,以期为IgG介导的神经免疫性疾病的精准治疗提供新思路。未来的研究应重点关注药物的长期安全性、适应证拓展及个体化治疗策略,以进一步提升其临床应用价值。展开更多
Five new-type Fc receptor molecules were constructed based on streptococcal protein G (SpG) and staphylococcal protein A (SpA). These protein molecules contain one to six Fc binding domains to immunoglobulins which ar...Five new-type Fc receptor molecules were constructed based on streptococcal protein G (SpG) and staphylococcal protein A (SpA). These protein molecules contain one to six Fc binding domains to immunoglobulins which are structurally different from native SpG or SpA. Their expression levels reached 17-30% of the total bacterial proteins after heat induction in E. colt. Immunodiffusion and ELISA results showed that the engineered protein TG (184 amino acid residues) composed of three SpG C3 domain could bind more broadly and efficiently than the native SpG to the IgGs of human, goat, rabbit, etc. , and its optimal pH for binding became wider (pH5-8) compared with the SpG (pH5) ; and the protein TGA (357AA), fused by protein TG and the A, B, C domains of SpA, displayed both the binding pattern of SpG and SpA.展开更多
To investigate the distribution of variant genotypes of Fc gamma receptor Ⅲa (FcγRⅢa) in healthy Chinese population of Zhengzhou city, genomic DNA was extracted from peripheral blood of healthy donators The genot...To investigate the distribution of variant genotypes of Fc gamma receptor Ⅲa (FcγRⅢa) in healthy Chinese population of Zhengzhou city, genomic DNA was extracted from peripheral blood of healthy donators The genotypes of FcγRⅢa-158 were determined by nested polymerase chain reaction (PCR) in 137 healthy people in Zhengzhou city The results showed that frequencies of variant genotypes FF, VV and VF were 42 3 %, 48 9 % and 8 8 % respectively The distribution of FcγRⅢa-158 in healthy Chinese population of Zhengzhou city was polymorphic and different from that of African Americans (AA) and Caucasian Americans (CA)展开更多
Objective To explore the roles of Fcγ recep tor in the pathogenesis of Graves' disease. Methods Fcγ receptor gene knockout mice(Fcγ R KO m ice) which were rooted in C57BL/6 mice and wild type C57BL/6 mice wer...Objective To explore the roles of Fcγ recep tor in the pathogenesis of Graves' disease. Methods Fcγ receptor gene knockout mice(Fcγ R KO m ice) which were rooted in C57BL/6 mice and wild type C57BL/6 mice were immunized by hTSH receptor expressing cells (DAP3.WT). 1-2×107 DAP3.WT cells were peri toneally injected into mice every two weeks for a total of six times. Two weeks after final immunization, mice were killed for measurement of total thyroxine, T RAb and pathological examination. Results The thyroxine level of the immunized Fcγ recept or gene knockout mice was significantly lower than that of the immunized wild ty pe control mice (2.2±0.31 vs. 3.32± 0.59 g·dL -1, P< 0.05 ),but there was no significant difference between immunized Fcγ R KO mic e and non-immunized wild type control group. The TRAb levels of the immunized F γ R KO mice significantly increased compared to those of the immunized wild type mice (21.75±8.21 vs. 14.11±6.21, P< 0.05). The lymphocyte cel ls infiltration and destruction of thyroid follicles were found in the thyroid gland of the immunized Fcγ R KO mice. Conclusion These results suggest that Fcγ receptor may be involved in the pathogenesis of Graves' disease.展开更多
The primers were designed according to the gene sequence of lipocalin protein family,and the gene sequence containing random mutation protein was obtained by overlapping extension of PCR.The random mutation lipocalin ...The primers were designed according to the gene sequence of lipocalin protein family,and the gene sequence containing random mutation protein was obtained by overlapping extension of PCR.The random mutation lipocalin library was constructed using phagemid expression vector.Lipocalin library was screened by subtracted screening of NSF60 cells and affinity screening of mast cells,and the lipocalin secondary library binding to mast cells was obtained.Then the lipocalin secondary library was enriched and screened with FcεRI-αreceptor protein as target molecule,and specific binding phages were eluted.After three rounds of screening,eight recombinant phage clones were randomly selected from elution clones of the third round.ELISA assay showed that three anticalin molecules could specifically bind to the FcεRI-αreceptor of mast cells.These results may provide some candidate biological molecules for the development of blocking drugs of mast cell FcεRI-αreceptor,and also lay the foundation for the development of biological small molecule drugs to treat Ig E associated allergic diseases.展开更多
Myasthenia gravis is a chronic autoimmune disorder that affects the neuromuscular junction leading to fluctuating skeletal muscle fatigability. The majority of myasthenia gravis patients have detectable antibodies in ...Myasthenia gravis is a chronic autoimmune disorder that affects the neuromuscular junction leading to fluctuating skeletal muscle fatigability. The majority of myasthenia gravis patients have detectable antibodies in their serum, targeting acetylcholine receptor, muscle-specific kinase, or related proteins. Current treatment for myasthenia gravis involves symptomatic therapy, immunosuppressive drugs such as corticosteroids, azathioprine, and mycophenolate mofetil, and thymectomy, which is primarily indicated in patients with thymoma or thymic hyperplasia. However, this condition continues to pose significant challenges including an unpredictable and variable disease progression, differing response to individual therapies, and substantial longterm side effects associated with standard treatments(including an increased risk of infections, osteoporosis, and diabetes), underscoring the necessity for a more personalized approach to treatment. Furthermore, about fifteen percent of patients, called “refractory myasthenia gravis patients”, do not respond adequately to standard therapies. In this context, the introduction of molecular therapies has marked a significant advance in myasthenia gravis management. Advances in understanding myasthenia gravis pathogenesis, especially the role of pathogenic antibodies, have driven the development of these biological drugs, which offer more selective, rapid, and safer alternatives to traditional immunosuppressants. This review aims to provide a comprehensive overview of emerging therapeutic strategies targeting specific immune pathways in myasthenia gravis, with a particular focus on preclinical evidence, therapeutic rationale, and clinical translation of B-cell depletion therapies, neonatal Fc receptor inhibitors, and complement inhibitors.展开更多
IgA Fc受体(FcαRI,CD89)属于免疫受体家族成员,主要表达于单核-巨噬细胞、中性粒细胞、嗜酸性粒细胞和树突状细胞等免疫效应细胞表面。FcαRI能特异的与血清型和分泌型IgA结合,并通过γ链介导一系列免疫反应,包括抗体依赖细胞介导的细...IgA Fc受体(FcαRI,CD89)属于免疫受体家族成员,主要表达于单核-巨噬细胞、中性粒细胞、嗜酸性粒细胞和树突状细胞等免疫效应细胞表面。FcαRI能特异的与血清型和分泌型IgA结合,并通过γ链介导一系列免疫反应,包括抗体依赖细胞介导的细胞毒性作用(ADCC)、补体依赖的细胞毒性(CDC)及细胞吞噬作用等。FcαRI是一种双功能受体,在不同的生理条件下可以介导免疫系统的活化和抑制反应。FcαRI在机体免疫防御和在维持系统免疫平衡方面扮演着重要的角色,有望成为治疗人类疾病的新靶点。本文对FcαRI的结构、功能及其应用等研究现状进行综述。展开更多
文摘新生儿Fc受体(neonatal Fc receptor,FcRn)通过与免疫球蛋G(immunoglobulin G,IgG)结合,延长其半衰期并促进再循环,是维持血清IgG稳态的重要受体。然而,致病性IgG的异常积累与多种神经免疫性疾病的发生密切相关。FcRn拮抗剂通过阻断FcRn与IgG的结合,可显著降低致病性IgG水平,从而有效地缓解相关疾病的临床症状。FcRn拮抗剂作为一种新兴的靶向治疗药物,展示了其治疗IgG介导的神经免疫性疾病的潜力。本文对FcRn拮抗剂的作用机制、种类和临床研究进展进行总结,以期为IgG介导的神经免疫性疾病的精准治疗提供新思路。未来的研究应重点关注药物的长期安全性、适应证拓展及个体化治疗策略,以进一步提升其临床应用价值。
文摘Five new-type Fc receptor molecules were constructed based on streptococcal protein G (SpG) and staphylococcal protein A (SpA). These protein molecules contain one to six Fc binding domains to immunoglobulins which are structurally different from native SpG or SpA. Their expression levels reached 17-30% of the total bacterial proteins after heat induction in E. colt. Immunodiffusion and ELISA results showed that the engineered protein TG (184 amino acid residues) composed of three SpG C3 domain could bind more broadly and efficiently than the native SpG to the IgGs of human, goat, rabbit, etc. , and its optimal pH for binding became wider (pH5-8) compared with the SpG (pH5) ; and the protein TGA (357AA), fused by protein TG and the A, B, C domains of SpA, displayed both the binding pattern of SpG and SpA.
文摘To investigate the distribution of variant genotypes of Fc gamma receptor Ⅲa (FcγRⅢa) in healthy Chinese population of Zhengzhou city, genomic DNA was extracted from peripheral blood of healthy donators The genotypes of FcγRⅢa-158 were determined by nested polymerase chain reaction (PCR) in 137 healthy people in Zhengzhou city The results showed that frequencies of variant genotypes FF, VV and VF were 42 3 %, 48 9 % and 8 8 % respectively The distribution of FcγRⅢa-158 in healthy Chinese population of Zhengzhou city was polymorphic and different from that of African Americans (AA) and Caucasian Americans (CA)
文摘Objective To explore the roles of Fcγ recep tor in the pathogenesis of Graves' disease. Methods Fcγ receptor gene knockout mice(Fcγ R KO m ice) which were rooted in C57BL/6 mice and wild type C57BL/6 mice were immunized by hTSH receptor expressing cells (DAP3.WT). 1-2×107 DAP3.WT cells were peri toneally injected into mice every two weeks for a total of six times. Two weeks after final immunization, mice were killed for measurement of total thyroxine, T RAb and pathological examination. Results The thyroxine level of the immunized Fcγ recept or gene knockout mice was significantly lower than that of the immunized wild ty pe control mice (2.2±0.31 vs. 3.32± 0.59 g·dL -1, P< 0.05 ),but there was no significant difference between immunized Fcγ R KO mic e and non-immunized wild type control group. The TRAb levels of the immunized F γ R KO mice significantly increased compared to those of the immunized wild type mice (21.75±8.21 vs. 14.11±6.21, P< 0.05). The lymphocyte cel ls infiltration and destruction of thyroid follicles were found in the thyroid gland of the immunized Fcγ R KO mice. Conclusion These results suggest that Fcγ receptor may be involved in the pathogenesis of Graves' disease.
基金The Science and Technology Project Foundation of Guangzhou,China(Grant No.201604020106)Natural Science Foundation of Guangdong Province(Grant No.1814050002837)
文摘The primers were designed according to the gene sequence of lipocalin protein family,and the gene sequence containing random mutation protein was obtained by overlapping extension of PCR.The random mutation lipocalin library was constructed using phagemid expression vector.Lipocalin library was screened by subtracted screening of NSF60 cells and affinity screening of mast cells,and the lipocalin secondary library binding to mast cells was obtained.Then the lipocalin secondary library was enriched and screened with FcεRI-αreceptor protein as target molecule,and specific binding phages were eluted.After three rounds of screening,eight recombinant phage clones were randomly selected from elution clones of the third round.ELISA assay showed that three anticalin molecules could specifically bind to the FcεRI-αreceptor of mast cells.These results may provide some candidate biological molecules for the development of blocking drugs of mast cell FcεRI-αreceptor,and also lay the foundation for the development of biological small molecule drugs to treat Ig E associated allergic diseases.
文摘Myasthenia gravis is a chronic autoimmune disorder that affects the neuromuscular junction leading to fluctuating skeletal muscle fatigability. The majority of myasthenia gravis patients have detectable antibodies in their serum, targeting acetylcholine receptor, muscle-specific kinase, or related proteins. Current treatment for myasthenia gravis involves symptomatic therapy, immunosuppressive drugs such as corticosteroids, azathioprine, and mycophenolate mofetil, and thymectomy, which is primarily indicated in patients with thymoma or thymic hyperplasia. However, this condition continues to pose significant challenges including an unpredictable and variable disease progression, differing response to individual therapies, and substantial longterm side effects associated with standard treatments(including an increased risk of infections, osteoporosis, and diabetes), underscoring the necessity for a more personalized approach to treatment. Furthermore, about fifteen percent of patients, called “refractory myasthenia gravis patients”, do not respond adequately to standard therapies. In this context, the introduction of molecular therapies has marked a significant advance in myasthenia gravis management. Advances in understanding myasthenia gravis pathogenesis, especially the role of pathogenic antibodies, have driven the development of these biological drugs, which offer more selective, rapid, and safer alternatives to traditional immunosuppressants. This review aims to provide a comprehensive overview of emerging therapeutic strategies targeting specific immune pathways in myasthenia gravis, with a particular focus on preclinical evidence, therapeutic rationale, and clinical translation of B-cell depletion therapies, neonatal Fc receptor inhibitors, and complement inhibitors.
